Events:

The company announces a positive profit forecast for the first half of 2023. It is expected that the company will record a comprehensive income growth of not less than 20% and a comprehensive net profit growth of not less than 30% as of June 2023:

1. It is estimated that the revenue growth in the first half of the year is not less than 20%, and the profit growth is not less than 30%:

The main driving force of the company's revenue growth during the period came from the significant increase in orders in many industries, such as the electronic chemicals sector and pharmaceuticals. By the end of 2022, the company's on-hand orders totaled 8.622 billion yuan, of which pharmaceutical and electronic chemicals were 2.35 billion yuan and 1.49 billion yuan respectively. For a long time, the company adheres to and benefits from the extensive coverage strategy of multi-industry and multi-plate, and achieves sustainable growth across cycles, industries and regions. The increase in the company's profits during the period was mainly due to the optimization of the company's marketing management, a reduction in sales and marketing expenses, and a reduction in share-based payment expenses.

two。 Deepen the construction of Alpha multi-track and accelerate the layout of global resources:

The company operates multiple tracks with emphasis on popular tracks, pursues the best return as the basis of resource allocation, and avoids dependence on a single market and a small number of customers. In the first half of 23 years, the company successfully delivered the EIPICO3 modular pharmaceutical plant project in Egypt, the first batch of JGC Basra refinery expansion project and the 5000-ton lithium hexafluorophosphate project signed with South Korea PGT, marking the company's rapid development in multi-plates. The company attaches importance to the expansion and incubation of the international supply chain, the continuous promotion of factory capacity in Malaysia, the function of the European technology center to promote the internationalization of biopharmaceutical business, and the construction of a talent and technology hub in Southeast Asia by the Mumbai Engineering Design Center.

3. Investment advice:

The company's revenue and profits maintain good growth, diversified business continues to develop, it is recommended to maintain attention.